Brief: Immuneering Announces Positive Data Update From Three Pancreatic Cancer Arms Of Ongoing Phase 2A Trial Of IMM-1-104

Immuneering

07/01/2025 12:16

Jan 7 (Reuters) - Immuneering Corp  IMRX.O :
    * IMMUNEERING ANNOUNCES POSITIVE DATA UPDATE FROM THREE
PANCREATIC
CANCER ARMS OF ONGOING PHASE 2A TRIAL OF IMM-1-104; PLANS TO
EXPAND TRIAL WITH ADDITIONAL ARMS
    * IMMUNEERING CORP - IMM-1-104 SHOWS 43% ORR AND 86% DCR IN
PANCREATIC CANCER
    * IMMUNEERING CORP - IMM-1-104 WITH FOLFIRINOX SHOWS 100%
LESION
REDUCTION IN PANCREATIC CANCER
    * IMMUNEERING CORP - FURTHER IMM-1-104 PHASE 2A DATA
EXPECTED IN
2Q’25

Source text:  ID:nGNX3YBJtN 
Further company coverage:  IMRX.O 

 ((Reuters.Brief@thomsonreuters.com))